Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00423709 · ClinicalTrials.gov registry record · NA
Allogeneic Blood Stem Cell Transplantation
A NA study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 46
- Enrollment target
NCT00423709: Completed NA study, sponsored by M.D. Anderson Cancer Center.
NCT00423709 is a NA study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00423709, a NA study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
Study Summary
1. To determine the feasibility and toxicity of employing allogeneic peripheral blood stem cell transplantation after intensive but non-myeloablative chemotherapy in patients with relapsed Hodgkin's disease (HD). 2. To determine the engraftment kinetics and degree of chimerism that can be achieved with this strategy. 3. To assess the antitumor activity of this approach in high-risk HD patients and the possible presence of a graft-vs-HD effect.
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- PROCEDURE Allogeneic Blood Stem Cell Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 1998-01 |
| Est. Completion | 2007-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00423709
The ClinicalTrials.gov registry entry for NCT00423709 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fludarabine is the first listed.
NCT00423709 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00423709 about?
NCT00423709 is a clinical study titled "Allogeneic Blood Stem Cell Transplantation". 1. To determine the feasibility and toxicity of employing allogeneic peripheral blood stem cell transplantation after intensive but non-myeloablative chemotherapy in patients with relapsed Hodgkin's disease (HD). 2. To determine the engraftment kinetics and degree of chimerism that can be achieved w...
What is the current status of trial NCT00423709?
This trial is currently completed. It is a NA study. The enrollment target is 46 participants. The study started on 1998-01. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00423709?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Allogeneic Blood Stem Cell Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00423709?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.